Barliana Melisa Intan, Ramdini Dwi Aulia, Afifah Nadiya Nurul, Alfian Sofa Dewi, Sumiwi Sri Adi
Department of Biological Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor, Indonesia.
Center of Excellence for Pharmaceutical Care Innovation, Universitas Padjadjaran, Jatinangor, Indonesia.
Patient Prefer Adherence. 2023 Nov 1;17:2737-2747. doi: 10.2147/PPA.S430083. eCollection 2023.
Optimizing long-term outcomes in schizophrenia treatment requires effective pharmacological interventions. Medication adherence is known to influence clinical outcomes, yet there is a scarcity of studies examining its correlation with factors like Length of Stay (LOS) and re-hospitalization frequency. These outcomes are crucial indicators of how medication adherence affects overall patient well-being.
This study aims to describe the effect of medication adherence on the length of stay (LOS) and number of hospitalizations in patients with schizophrenia.
A total of 157 subjects from the West Java Psychiatric Hospital were included in this cross-sectional retrospective study. Data, including demographics, comorbidities, duration of illness, antipsychotic adherence, LOS, and the number of hospitalizations, were collected from the patients' medical records. All the data were analyzed using the Chi-Square (χ²) test with a significance level set at p < 0.05.
Our findings showed that 88% of all schizophrenia inpatients were in the nonadherence group. The highest (40.7%) LOS (>30 days) was found in the non-adherence group with discontinued therapy/stopped therapy group, while the highest percentage of patients with less than five hospitalizations was identified in the obedient and regular therapy group (94.4%). In the statistical results, we observed a significant association between therapy adherence (p = 0.043) and therapy regimen (p = 0.014) with gender. Additionally, the distinction between male and female schizophrenia patients demonstrated statistical significance (p = 0.000).
In this study, therapy adherence and therapy regimen were found to have a significant association with gender, as well as differences between the number of male and female schizophrenia patients that were statistically significant. While other variables may exhibit clinical associations, their statistical significance has not been fully depicted. The results of this study could be preliminary study for subsequent observational studies.
优化精神分裂症治疗的长期效果需要有效的药物干预。已知药物依从性会影响临床结果，但缺乏研究探讨其与住院时间（LOS）和再住院频率等因素的相关性。这些结果是药物依从性如何影响患者整体福祉的关键指标。
本研究旨在描述药物依从性对精神分裂症患者住院时间（LOS）和住院次数的影响。
本横断面回顾性研究纳入了西爪哇精神病院的157名受试者。从患者的病历中收集数据，包括人口统计学、合并症、病程、抗精神病药物依从性、LOS和住院次数。所有数据均使用卡方（χ²）检验进行分析，显著性水平设定为p < 0.05。
我们的研究结果表明，所有精神分裂症住院患者中有88%属于非依从组。在非依从组中的停药/停药治疗组中，住院时间最长（>30天）的比例最高（40.7%），而在顺从和规律治疗组中，住院次数少于5次的患者比例最高（94.4%）。在统计结果中，我们观察到治疗依从性（p = 0.043）和治疗方案（p = 0.014）与性别之间存在显著关联。此外，男性和女性精神分裂症患者之间的差异具有统计学意义（p = 0.000）。
在本研究中，发现治疗依从性和治疗方案与性别存在显著关联，并且男性和女性精神分裂症患者的数量差异具有统计学意义。虽然其他变量可能显示出临床关联，但其统计学意义尚未完全描述。本研究结果可为后续观察性研究提供初步研究。
